Oxalic Acid

Oxalic Acid

SCHEMBL7616181

Cc1cccc(CCCOc2nsnc2C2=CCCN(C)C2)c1.O=C(O)C(=O)O

nearest known ligand 0.74

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRM1SLC6A4

The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 9/20 0.70
CHRM4 P08173 4/20 0.60
CHRM2 P08172 1/20 0.60
CHRM5 P08912 1/20 0.60
CHRM3 P20309 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6915118 0.94 CHRM1 (0.74) CHRM1CHRM4CHRM2CHRM5CHRM3
Oxalic Acid SCHEMBL7611099 0.91 CHRM1 (0.85) CHRM1CHRM4CHRM2CHRM5CHRM3
Oxalic Acid SCHEMBL7618898 0.89 CHRM1 (0.72) CHRM1CHRM4CHRM2CHRM5CHRM3
Oxalic Acid SCHEMBL7613640 0.88 CHRM1 (0.66) CHRM1CHRM4CHRM2CHRM5CHRM3
Oxalic Acid SCHEMBL7617499 0.86 CHRM1 (0.65) CHRM1CHRM4CHRM2CHRM5CHRM3
Oxalic Acid SCHEMBL7612053 0.86 CHRM1 (0.62) CHRM1CHRM4CHRM2CHRM5CHRM3
Oxalic Acid SCHEMBL7613498 0.86 CHRM1 (0.60) CHRM1CHRM4CHRM2CHRM5CHRM3
SCHEMBL6906714 0.86 CHRM1 (0.94) CHRM1CHRM4CHRM2CHRM5CHRM3
Oxalic Acid SCHEMBL7617360 0.84 CHRM1 (0.71) CHRM1CHRM4CHRM2CHRM5CHRM3
Oxalic Acid SCHEMBL7612748 0.84 CHRM1 (0.71) CHRM1CHRM4CHRM2CHRM5CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0734259-B1 Use of piperidine compounds in the treatment of schizophrenia NOVO NORDISK AS (DK) 2002-06-12 EP disclosed
US-5773452-A ALZHEIMER'S DISEASE; COGNITION ACTIVATORS NOVO NORDISK ALS (DK) 1998-06-30 US disclosed
US-5753683-A SCHIZOPHRENIA NOVO NORDISK A/S (DK) 1998-05-19 US disclosed
US-5750541-A 3-(1,2,5-THIA OR OXADIAZOL-3-YL)-1,2,5,6-PYRIDINE DERIVATIVES; SCHIZOPHRENIFORM DISEASES; SIDE EFFECT REDUCTION NOVO NORDISK A/S (DK) 1998-05-12 US disclosed
US-5744489-A ADMINISTERING CERTAIN 1,2,5-THIADIAZOLE AND 1,2,5-OXADIAZOLE COMPOUNDS GREENWOOD BEVERLEY (US) 1998-04-28 US disclosed
US-5565475-A Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives MUHLHAUSER MARK A (US) 1996-10-15 US disclosed
EP-0734259-A1 ANTIPSYCHOTIC METHOD NOVO NORDISK A/S (DK) 1996-10-02 EP disclosed
EP-0732925-A1 A METHOD OF TREATING GASTROINTESTINAL MOTILITY DISORDERS NOVO NORDISK A/S (DK) 1996-09-25 EP disclosed
US-5545638-A USING A 3-(TETRAHYDROPYRID-3-YL-) SUBSTITUTED (OXA- OR THIA-)DIAZOLE COMPOUND NOVO NORDISK A/S (DK) 1996-08-13 US disclosed
WO-1995017185-A1 A METHOD OF TREATING GASTROINTESTINAL MOTILITY DISORDERS NOVO NORDISK A/S (DK) 1995-06-29 WO disclosed
WO-1995005174-A1 ANTIPSYCHOTIC METHOD NOVO NORDISK A/S (DK) 1995-02-23 WO disclosed